Table 1.
Pharmacokinetic Parameters for Isotope Assessment in Plasma and Urine
| Parameter | Intervention, Geometric Mean Value (95% CI) |
||
|---|---|---|---|
| Normosol-R | Nonoxynol-9 | CS + BX | |
| Plasma AUC, fraction of dose-h × 10–5 | 0.61 (.27–1.36) | 5.06 (3.61–7.10)a,b | 0.90 (.56–1.44) |
| Plasma Cmax, fraction of dose × 10–5 | 0.06 (.03–.14) | 0.74 (.50–1.09)a,b | 0.09 (.05–.14) |
| Plasma Tmax, h after intervention receipt | 5.3 (3.5–8.2)b | 1.1 (.9–1.4)a,b | 2.8 (1.8–4.3) |
| 99mTc dose retained after receipt, µCi | 496 (484–508)b | 528 (508–548)a,b | 449 (417–483) |
| Fraction of 99mTc detected in urine 0–24 h after intervention receipt, % of dose | 1.6 (.5–5.5) | 6.5 (4.2–9.9)a,b | 2.6 (1.2–5.3) |
| Time to first bowel movement, h after intervention receipt | 4.5 (1.7–11.9) | 2.0 (1.0–4.3) | 3.8 (1.6– 9.2) |
Abbreviations: AUC, area under the curve; CI, confidence interval; Cmax, maximum concentration; CS + BX, Normosol-R plus coital simulation and endoscopic biopsy; Tmax, time to maximum concentration; 99mTc, 99mtechnetium.
a P < .05, compared with Normosol-R, using the t test for pair-wise comparison.
b P < .05, compared with CS + BX, using the t test for pair-wise comparison.